Tarun Aurora
Hematology · Atlanta, GANPI 1578927356
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,200 of the $6,392 with a category attached, or 81.4%. Novo Nordisk accounts for 81.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $5,763, more than ten times the $48 reported in 2021. That places this record below the midpoint for hematology clinicians in GA, where the typical reported total is $6,392.
Across 19 payments — averaging $336.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$5K
- Genetix Biotherapeutics Inc$405
- Pfizer$134
- Lilly USA, LLC$133
- AstraZeneca$113
- Sobi, Inc$103
- plus $304 from 7 others
What the payments were for
- Consulting fees$5,20081%
- Food & beverage$1,08517%
- Education$1072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $5,200 |
| Genetix Biotherapeutics Inc | 4 | $405 |
| Pfizer | 1 | $134 |
| Lilly USA, LLC | 2 | $133 |
| AstraZeneca | 1 | $113 |
| Sobi, Inc | 1 | $103 |
| Sanofi | 1 | $97 |
| Vertex | 2 | $81 |
| Seagen Inc. | 2 | $48 |
| Adaptive Biotechnologies Corporation | 1 | $26 |
| Bristol Myers Squibb | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,392 in reported general payments places this provider in the 50th percentile of 27 hematology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 13 | $7,469 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $961 |
| Oxycodone Hcl | 45 | $727 |
| Morphine Sulfate ErMorphine Sulfate | 20 | $609 |
| Hydroxyurea | 17 | $345 |
Paid to pharmacies, not to this prescriber.
Other hematology in Atlanta
- Sagar LonialAtlanta$1.6M
- Edmund WallerAtlanta$119K
- Craig HofmeisterAtlanta$50K
- Lorraine CafuirAtlanta$41K
- Christine KemptonAtlanta$38K
- Manila GaddhAtlanta$37K
- Kenneth BraunsteinAtlanta$33K
- Duc TranAtlanta$32K
- Mary Jo LechowiczAtlanta$18K
- Martha ArellanoAtlanta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.